AstraZeneca drug Fasenra fails to achieve main goal in COPD trial

AstraZeneca's (AZN.L) first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).